Budget and Health Impact of Switching Eligible Patients with Atrial Fibrillation to Lower- Dose Dabigatran
Abstract
Share and Cite
Fens, T.; de Jong, L.; Kappelhoff, B.; Boersma, C.; Postma, M.J. Budget and Health Impact of Switching Eligible Patients with Atrial Fibrillation to Lower- Dose Dabigatran. J. Mark. Access Health Policy 2023, 11, 2247719. https://doi.org/10.1080/20016689.2023.2247719
Fens T, de Jong L, Kappelhoff B, Boersma C, Postma MJ. Budget and Health Impact of Switching Eligible Patients with Atrial Fibrillation to Lower- Dose Dabigatran. Journal of Market Access & Health Policy. 2023; 11(1):2247719. https://doi.org/10.1080/20016689.2023.2247719
Chicago/Turabian StyleFens, Tanja, Lisa de Jong, Bregt Kappelhoff, Cornelis Boersma, and Maarten J. Postma. 2023. "Budget and Health Impact of Switching Eligible Patients with Atrial Fibrillation to Lower- Dose Dabigatran" Journal of Market Access & Health Policy 11, no. 1: 2247719. https://doi.org/10.1080/20016689.2023.2247719